Trulieve Announces Uplist to NYSE
Rhea-AI Summary
Trulieve (NYSE: TRLV) received approval to list its subordinate voting shares on the New York Stock Exchange, with trading expected to begin June 10, 2026 under ticker TRLV.
The company reports 206 state-licensed medical marijuana dispensaries and 3.5 million square feet of DEA-registered production capacity after a recent restructuring.
AI-generated analysis. Not financial advice.
Positive
- NYSE uplisting with TRLV trading expected to start June 10, 2026
- First U.S. cannabis company to list on a major U.S. exchange
- 206 medical marijuana dispensaries in consolidated operations
- 3.5 million sq. ft. of DEA-registered production capacity
- Corporate restructuring focused on state-licensed medical marijuana operations
- Management cites robust cash generation and expansion catalysts in Georgia and Texas
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
TCNNF gained 16.03%, outpacing peers: GTBIF up 5.17%, CURLF up 3.7%, NDOI up 0.23%, while NIKA and EVOTF were flat. The move appears company-specific to the NYSE uplist.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 13 | Corporate domestication plan | Neutral | -3.9% | Announced plan to domesticate from British Columbia to Delaware. |
| May 07 | Q1 2026 earnings | Positive | -4.9% | Reported profitable Q1 with strong gross margin and cash generation. |
| May 05 | New dispensary opening | Positive | +5.7% | Announced opening of a new medical cannabis dispensary in Florida. |
| Apr 29 | DEA applications filed | Positive | -4.2% | Filed DEA registration applications for state-licensed medical operations. |
| Apr 23 | Federal rescheduling news | Positive | -6.6% | Applauded federal rescheduling of medical marijuana to Schedule III. |
Recent history shows multiple positive or strategic announcements followed by negative price reactions, suggesting a tendency to sell into good news, with occasional rallies on localized growth updates.
Over the last several months, Trulieve reported a profitable Q1 2026 with $287M revenue and strong margins, yet the stock fell after earnings. Regulatory milestones such as DEA registration applications and the federal rescheduling of medical marijuana to Schedule III on April 23, 2026 also saw negative reactions. By contrast, a localized growth update about opening a Belleview, Florida dispensary on May 8, 2026 coincided with a price gain. A proposed domestication to Delaware in August 2026 planning likewise saw a modest decline, underscoring mixed reactions to structural news.
Market Pulse Summary
This announcement details Trulieve’s planned NYSE uplist under ticker TRLV and highlights its repositioning as a DEA-registered, medical-only operator with 206 dispensaries and 3.5 million square feet of capacity. It follows U.S. rescheduling of medical marijuana to Schedule III and a corporate restructuring to deconsolidate mixed-use operations. Investors evaluating this development can track execution on the new structure, subsequent SEC filings, and how trading on a major exchange interacts with prior patterns around earnings and regulatory milestones.
Key Terms
new york stock exchange financial
schedule iii regulatory
drug enforcement administration regulatory
executive order regulatory
united nations single convention on narcotic drugs regulatory
AI-generated analysis. Not financial advice.
Subordinate Voting Shares expected to begin trading under ticker "TRLV" on Wednesday, June 10
"As the first
Acting Attorney General Todd Blanche reclassified medical marijuana to Schedule III in April 2026, following an Executive Order by President Trump in December 2025. The final order issued in April rescheduled state licensed medical marijuana products and created a pathway for Drug Enforcement Administration ("DEA") registration for state licensed medical marijuana businesses under the treaty authority pursuant to the United Nations Single Convention on Narcotic Drugs.
Following medical marijuana rescheduling, Trulieve completed a corporate restructuring and investment by a third party resulting in the deconsolidation of operations in markets serving both medical and adult use customers. Trulieve's remaining consolidated operations consist only of state licensed medical marijuana facilities and include 206 medical marijuana dispensaries supported by 3.5 million square feet of production capacity registered with the DEA.
"Since inception, Trulieve has focused on serving medical patients with compassion, care, and high quality products," said Kim Rivers. "With robust cash generation and meaningful catalysts ahead including expansion in
The Company anticipates the Subordinate Voting Shares will continue trading on the Canadian Securities Exchange ("CSE") under the symbol "TRUL" and the OTCQX under the symbol "TCNNF" until the close of market on June 9, 2026. Current shareholders of the Company do not need to take any action prior to the Company's expected listing on the NYSE.
Forward-Looking Statements
This news release includes forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. These forward-looking statements relate to the Company's expectations or forecasts and other plans, intentions, expectations, estimates, and beliefs and include, among other things, statements regarding the expected listing of the Subordinate Voting Shares on the NYSE and delisting from the CSE and OTCQX, expansion of the Company's shareholder base, enhanced liquidity of the Subordinate Voting Shares and expansion in the states of Georgia and Texas. Words such as "expects", "continue", "will", "anticipates", and "intends" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company's current projections and expectations about future events and trends that management believes might affect its financial condition, results of operations, business strategy, and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions, and expected future developments and other factors management believes are appropriate. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein, including, without limitation, the risks discussed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 and in our periodic reports subsequently filed with the U.S. Securities and Exchange Commission and in the Company's filings on SEDAR+ at www.sedarplus.ca. There can be no assurance that any forward-looking information and statements herein will prove to be accurate, and accordingly, readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof and, except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking information and statements herein, whether as a result of new information, future events or results, or otherwise.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia. Driven by a core mission to expand access to cannabis, Trulieve serves customers with innovative, high-quality branded products and exceptional experiences. With scaled operations in attractive markets and targeted expansion through its hub strategy, Trulieve is poised for accelerated growth. Trulieve is currently listed on the CSE under the symbol TRUL and currently trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve
X: @Trulieve
Investor and Media Contact
Christine Hersey, Chief Corporate Affairs and Strategy Officer
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-announces-uplist-to-nyse-302792168.html
SOURCE Trulieve Cannabis Corp.